Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT targeting neoantigens, we focused on TP53 muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sanghyun P., Vale, Nolan R., Zacharakis, Nikolaos, Krishna, Sri, Yu, Zhiya, Gasmi, Billel, Gartner, Jared J., Sindiri, Sivasish, Malekzadeh, Parisa, Deniger, Drew C., Lowery, Frank J., Parkhurst, Maria R., Ngo, Lien T., Ray, Satyajit, Li, Yong F., Hill, Victoria, Florentin, Maria, Masi, Robert V., Paria, Biman C., Levin, Noam, Bera, Alakesh, Hedges, Elizabeth A., Choi, Agnes, Chatani, Praveen D., Parikh, Anup Y., Levi, Shoshana, Seitter, Samantha, Lu, Yong-Chen, Zheng, Zhili, Prickett, Todd D., Jia, Li, Hernandez, Jonathan M., Hoang, Chuong D., Robbins, Paul F., Goff, Stephanie L., Sherry, Richard M., Yang, James C., Rosenberg, Steven A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357191/
https://www.ncbi.nlm.nih.gov/pubmed/35749374
http://dx.doi.org/10.1158/2326-6066.CIR-22-0040

Ejemplares similares

Ejemplares similares